Takeda announces clinical trial for anti-Zika vaccine

Japan-based Takeda has announced a Phase I clinical trial for its anti-Zika (TAK-426) vaccine. The trial will have a minimum duration of 15 months and will be partly funded by the US Department of Health and Human Services, the Office of the Assistant Secretary for Preparedness and Response and the Biomedical Advanced Research and Development Authority (BARDA). The new candidate will compete with the vaccine developed by France-based Sanofi, which has seemingly experienced issues in manufacturing it.

(Source: Takeda)